CMS·2025-04-24 08:02Investment Rating - The report maintains an "Accumulate" investment rating for the company [3]. Core Insights - The company reported a revenue of 1.541 billion yuan in Q1 2025, representing a year-over-year increase of 10.10%, and a net profit of 327 million yuan, up 15.83% year-over-year [1]. - The net profit margin improved to approximately 21.06% in Q1 2025, an increase of 1.09 percentage points year-over-year and 6.91 percentage points quarter-over-quarter, attributed to cost reduction measures and rapid growth in emerging businesses [6]. - The small molecule CDMO business showed stable progress with revenue approximately at 1.223 billion yuan, maintaining year-over-year stability, while the emerging service business grew over 80% year-over-year, with revenue exceeding 317 million yuan in Q1 2025 [6]. - The company aims for double-digit revenue growth for the full year, supported by strong order trends, particularly from European and American clients, with a projected revenue of 6.617 billion yuan for 2025 [6]. Financial Data and Valuation - The company’s total revenue is projected to decline by 24% in 2023, followed by a 26% decline in 2024, before recovering with a 14% growth in 2025 [2][10]. - The estimated earnings per share (EPS) for 2025 is 2.99 yuan, with a price-to-earnings (PE) ratio of 22.4 [2][10]. - The company’s return on equity (ROE) is projected to be 6% in 2025, with a gradual increase to 8% by 2027 [10]. Shareholder Information - The major shareholder, ASYMCHEM LABORATORIES INCORPORATED, holds a 31.93% stake in the company [3]. Market Performance - The company's stock price is currently at 67.06 yuan, with a total market capitalization of 24.2 billion yuan [3].